Advertisement

Trans-resveratrol Inhibits Tau Phosphorylation in the Brains of Control and Cadmium Chloride-Treated Rats by Activating PP2A and PI3K/Akt Induced-Inhibition of GSK3β

  • Ali A. ShatiEmail author
  • Mohammad Y. Alfaifi
Original Paper
  • 70 Downloads

Abstract

This study investigated if resveratrol (RES) can protect against cadmium chloride (CdCl2)-induced memory loss and Tau protein hyperphosphorylation in rats and explored its effect on AMPK/PI3K/Akt signaling pathway. Rats (n = 10/group) were divided into seven groups as: control; control + DMSO; control + LY294002, a selective PI3K inhibitor (0.25 µg/100 g, i.p); control + RES (300 mg/kg, orally); CdCl2 (5 mg/kg, orally); CdCl2 + RES and CdCl2 + RES + LY294002. All treatments were carried out for 30 consecutive days on a daily basis. RES improved both short and long-term memory as analyzed by novel object recognition task and significantly increased brain levels of glutathione in both control and CdCl2-treated rats. It also inhibited ROS levels of malondialdehyde in the brains of CdCl2-treated rats. In both groups, RES decreased the phosphorylation rate of Tau at Ser199 and Ser296. Concomitantly, it significantly increased protein levels of p-GSK3β (Ser9) and p-PP2A and decreased p-GSK3β (Tyr216). Also, RES activated PI3K/Akt signaling pathway in both control and CdCl2 treated rats by increasing levels of p-PI3K (Tyr607) and p-Akt (Ser473). This was concomitant with significant increase in the levels of AMPK and p-AMPK, known upstream regulators of PI3K/Akt signaling pathway. Interestingly, all the above listed beneficial effects of RES, except their effect on AMPK/p-AMPK, were completely abolished in CdCl2 + RES + LY294002-treated rats. In conclusion, in addition to its antioxidant potential, RES inhibits Tau phosphorylation in rat’s brain by activating PP2A protein and AMPK/PI3K/Akt-induced inhibition of GSK3β.

Keywords

Resveratrol Cadmium Brain Tau Memory, PI3K/Akt 

Notes

Acknowledgements

The authors would like to thank Mr. Mahmoud Alkhateeb from King Saud University for Health Sciences for his partial contribution to this study. They would like to thank the animal facility staff at King Khalid University for taking of animals during the experimental procedure.

Author Contributions

Both AS and MA contributed equally to this work. AS and MA designed the experimental procedure and supervised the treatment and sample collections. MA performed the behavioral analysis and measured some of the biochemical parameters of this study. AS performed all the western blotting measurements. AS and MA collected the data, analyzed them and graphed the data. AS wrote the draft of the manuscript and MA finalized the final version.

Funding

The authors extend their appreciation to the Deanship of Scientific Research at King Khalid University for funding this work through General Research Project under grant number (201/39).

Compliance with Ethical Standards

Conflict of interest

The authors declare that there is no conflict of interests.

Supplementary material

11064_2018_2683_MOESM1_ESM.docx (28 kb)
Supplementary material 1 (DOCX 27 KB)

References

  1. 1.
    Selkoe DJ (2011) Alzheimer’s disease. Cold Spring Harb Perspect Biol 3:1–16CrossRefGoogle Scholar
  2. 2.
    Fath T, Eidenmüller J, Brandt R (2002) Tau-mediated cytotoxicity in a pseudohyperphosphorylation model of Alzheimer’s disease. J Neurosci 2:9733–9741CrossRefGoogle Scholar
  3. 3.
    Zempel H, Luedtke J, Kumar Y, Biernat J, Dawson H, Mandelkow E, Mandelkow EM (2013) Amyloid-β oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin. EMBO J 32:2920–2937PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Swomley AM, Förster S, Keeney JT, Triplett J, Zhang Z, Sultana R, Butterfield DA (2013) A beta, oxidative stress in Alzheimer disease: evidence based on proteomics studies. Biochim Biophys Acta 1842:1248–1257PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Alonso AC, Li B, Grundke-Iqbal I, Iqbal K (2008) Mechanism of Tau-induced neurodegeneration in Alzheimer disease and related tauopathies. Curr Alzheimer Res 5:375–384PubMedCrossRefGoogle Scholar
  6. 6.
    Landrieu I, Smet-Nocca C, Amniai L, Louis JV, Wieruszeski JM, Goris J, Janssens V, Lippens G (2011) Molecular implication of PP2A and Pin1 in the Alzheimer’s disease specific hyperphosphorylation of Tau. PLoS ONE 6:e21521PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Rankin CA, Sun Q, Gamblin TC (2007) Tau phosphorylation by GSK-3β promotes tangle-like filament morphology. Mol Neurodegener 2:12PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Ponce-Lopez T, Hong E, Abascal-Díaz M, Meneses A (2017) Role of GSK3β and PP2A on regulation of Tau phosphorylation in hippocampus and memory impairment in ICV-STZ animal model of Alzheimer’s disease. Adv Alzheimer’s Dis 2017:13–31CrossRefGoogle Scholar
  9. 9.
    Lee CW, Lau KF, Miller CC, Shaw PC (2003) Glycogen synthase kinase-3β-mediated Tau phosphorylation in cultured cell lines. Neuroreport 14:257–260PubMedCrossRefGoogle Scholar
  10. 10.
    Noh MY, Koh SH, Kim Y, Kim HY, Cho GW, Kim SH (2009) Neuroprotective effects of donepezil through inhibition of GSK-3 activity in amyloid-betainduced neuronal cell death. J Neurochem 108:1116–1125PubMedCrossRefGoogle Scholar
  11. 11.
    Mulot S, Hughes K, Woodgett J, Anderton BH, Hanger DP (1994) PHF-Tau from Alzheimer’s brain comprises four species on SDS-PAGE which can be mimicked by in vitro phosphorylation of human brain Tau by glycogen synthase kinase-3b. FEBS Lett 349:359–364PubMedCrossRefGoogle Scholar
  12. 12.
    Singh TJ, Zaidi T, Grundke-Iqbal I, Iqbal K (1995) Modulation of GSK-3-catalyzed phosphorylation of microtubule-associated protein Tau by non-proline-dependent protein kinases. FEBS Lett 358:4–8PubMedCrossRefGoogle Scholar
  13. 13.
    Iqbal K, Liu F, Gong C (2014) Alzheimer disease therapeutics: focus on the disease and not just plaques and tangles. Biochem Pharmacol 88:631–639PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Xiao H, Wang J, Yuan L, Xiao C, Wang Y, Liu X (2013) Chicoric acid induces apoptosis in 3T3-L1 preadipocytes through ROS-mediated PI3K/Akt and MAPK signaling pathways. J Agric Food Chem 61:1509–1520PubMedCrossRefGoogle Scholar
  15. 15.
    Zhao R, Zhang Z, Song Y, Wang D, Qi J, Wen S (2011) Implication of phosphatidylinositol-3 kinase/Akt/glycogen synthase kinase-3β pathway in ginsenoside Rb1’s attenuation of beta-amyloid-induced neurotoxicity and Tau phosphorylation. J Ethnopharmacol 133:1109–1116PubMedCrossRefGoogle Scholar
  16. 16.
    Min KJ, Lee JT, Joe EH, Kwon TK (2011) An IκBα phosphorylation inhibitor induces hemeoxygenase-1(HO-1) expression through the activation of reactive oxygen species (ROS)-Nrf2-ARE signaling and ROS-PI3K/Akt signaling in an NF-κB-independent mechanism. Cell Signal 23:1505–1513PubMedCrossRefGoogle Scholar
  17. 17.
    Hu W, Li F, Mahavadi S, Murthy KS (2009) Upregulation of RGS4 expression by IL-1beta in colonic smooth muscle is enhanced by ERK1/2 and p38 MAPK and inhibited by the PI3K/Akt/GSK3β pathway. Am J Physiol Cell Physiol 296:1310–1320CrossRefGoogle Scholar
  18. 18.
    Yegambaram M, Manivannan B, Beach TG, Halden RU (2015) Role of environmental contaminants in the etiology of Alzheimer’s disease: a review. Curr Alzheimer Res 12:116–146PubMedCrossRefGoogle Scholar
  19. 19.
    Wang B, Du Y (2013) Cadmium and its neurotoxic effects. Oxidative medicine and cellular longevity: article ID 898034Google Scholar
  20. 20.
    Godt J, Scheidig F, Grosse-Siestrup C, Esche V, Brandenburg P, Reich A (2006) The toxicity of cadmium and resulting hazards for human health. J Occup Med Toxicol 1:1–6CrossRefGoogle Scholar
  21. 21.
    Nawrot T, Plusquin M, Hogervorst J, Roels HA, Celis H, Thijs L (2006) Environmental exposure to cadmium and risk of cancer: a prospective populationbased study. Lancet Oncol 7:119–126PubMedCrossRefGoogle Scholar
  22. 22.
    Shukla A, Shukla GS, Srimal RC (1996) Cadmium-induced alterations in blood-brain barrier permeability and its possible correlation with decreased microvessel antioxidant potential in rat. Hum Exp Toxicol 15:400–405PubMedCrossRefGoogle Scholar
  23. 23.
    Barnham KJ, Bush AI (2008) Metals in Alzheimer’s and Parkinson’s diseases. Curr Opin Chem Biol 12:222–228PubMedCrossRefGoogle Scholar
  24. 24.
    Panayi A, Spyrou N, Iversen B, White MA, Part P (2002) Determination of cadmium and zinc in Alzheimer’s brain tissue using inductively coupled plasma mass spectrometry. J Neurol Sci 195:1–10PubMedCrossRefGoogle Scholar
  25. 25.
    Jiang LF, Yao TM, Zhu ZL, Wang C, Ji LN (2007) Impacts of Cd (II) on the conformation and self-aggregation of Alzheimer’s Tau fragment corresponding to the third repeat of microtubule-binding domain. Biochim Biophys Acta 1774:1414–1421PubMedCrossRefGoogle Scholar
  26. 26.
    Chen L, Xu B, Liu L, Zhou H, Chen W, Shen T, Shen T, Han X, Kontos CD, Huang S (2011) Cadmium induction of reactive oxygen species activates the mTOR pathway, leading to neuronal cell death. Free Radic Biol Med 50:624–632PubMedCrossRefGoogle Scholar
  27. 27.
    Goncalves JF, Fiorenza AM, Spanevello RM, Mazzanti CM, Bochi GV, Antes FG, Stefanello N, Rubin MA, Dressler VL, Morsch VM, Schetinger MR (2010) N-Acetylcysteine prevents memory deficits, the decrease in acetylcholinesterase activity and oxidative stress in rats exposed to cadmium. Chem Biol Interact 186:53–60PubMedCrossRefGoogle Scholar
  28. 28.
    Shukla GS, Srivastava RS, Chandra SV (1988) Glutathione status and cadmium neurotoxicity: studies in discrete brain regions of growing rats. Fundam Appl Toxicol 11:229–235PubMedCrossRefGoogle Scholar
  29. 29.
    Wang Y, Fang J, Leonard SS, Rao KM (2004) Cadmium inhibits the electron transfer chain and induces reactive oxygen species. Free Radic Biol Med 36:1434–1443PubMedCrossRefGoogle Scholar
  30. 30.
    del Pino J, Zeballos G, Anadón MJ, Moyano P, Díaz MJ, García JM (2015) Cadmium-induced cell death of basal forebrain cholinergic neurons mediated by muscarinic M1 receptor blockade, increase in GSK-3b enzyme, b-amyloid and Tau protein levels. Arch Toxicol 1:12Google Scholar
  31. 31.
    Chen L, Liu L, Huang S (2008) Cadmium activates the mitogen activated protein kinase (MAPK) pathway via induction of reactive oxygen species and inhibition of protein phosphatases 2A and 5. Free Radic Biol Med 45:1035–1044PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Chen S, Xu Y, Xu B, Guo M, Zhang Z, Liu L, Ma H, Chen Z, Luo Y, Huang S, Chen L (2011) Ca MKII is involved in cadmium activation of MAPK and mTOR pathways leading to neuronal cell death. J Neurochem 119:1108–1118PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Pei JJ, Hugon J (2008) mTOR-dependent signalling in Alzheimer’s disease. J Cell Mol Med 12:2525–2532PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Tang Z, Bereczki E, Zhang H, Wang S, Li C, Ji X, Branca RM, Lehtiö J, Guan Z, Filipcik P, Xu S, Winblad B, Pei JJ (2013) Mammalian target of rapamycin (mTor) mediates Tau protein dyshomeostasis implication for Alzheimer disease. J Biol Chem 288:15556–15570PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Bastianetto S, Zheng WH, Quirion R (2000) Neuroprotective abilities of resveratrol and other red wine constituents against nitric oxide-related toxicity in cultured hippocampal neurons. Br J Pharmacol 131:711–720PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Virgili M, Contestabile A (2000) Partial neuroprotection of in vivo excitotoxic brain damage by chronic administration of the red wine antioxidant agent, trans-resveratrol in rats. Neurosci Lett 281:123–126PubMedCrossRefGoogle Scholar
  37. 37.
    Nicolini G, Rigolio R, Miloso M, Bertelli AA, Tredici G (2001) Anti-apoptotic effect of trans-resveratrol on paclitaxel-induced apoptosis in the human neuroblastoma SH-SY5Y cell line. Neurosci Lett 302:41–44PubMedCrossRefGoogle Scholar
  38. 38.
    Leibovici D, Ritchie K, Ledésert B, Touchon J (1999) The effects of wine and tobacco consumption on cognitive performance in the elderly: a longitudinal study of relative risk. Int J Epidemiol 28:77–81PubMedCrossRefGoogle Scholar
  39. 39.
    Orgogozo JM, Dartigues JF, Lafont S, Letenneur L, Commenges D, Salamon R, Renaud S, Breteler MB (1997) Wine consumption and dementia in the elderly: A prospective community study in the. Bordx Rev Neurol 153:185–192PubMedPubMedCentralGoogle Scholar
  40. 40.
    Rege SD, Geetha T, Griffin GD, Broderick TL, Babu J (2014) Neuroprotective effects of resveratrol in Alzheimer disease pathology. Front Aging Neurosci 11:218Google Scholar
  41. 41.
    Karuppagounder SS, Pinto JT, Xu H (2009) Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer’s disease. Neurochem Int 54:111–118PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Porquet D, Grinan-Ferre C, Ferrer I, Camins A, Sanfeliu C, Del Valle J (2014) Neuroprotective role of trans-resveratrol in a murine model of familial Alzheimer’s disease. J Alzheimers Dis 42:1209–1220PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Frozza RL, Bernardi A, Hoppe JB, Meneghetti AB, Matté A, Battastini AM, Pohlmann AR, Guterres SS, Salbego C (2013) Neuroprotective effects of resveratrol against Aβ administration in rats are improved by lipid-core nanocapsules. Mol Neurobiol 47:1066–1080PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Lin F, Peng Y, Yang QH, MI XJ (2015) Resveratrol inhibits cadmium induced neuronal apoptosis by modulating calcium signalling pathway via regulation of MAPK/mTOR network. Bangladesh J Pharmacol 10:366–376CrossRefGoogle Scholar
  45. 45.
    Liu C, Zhang R, Sun C, Zhang H, Xu C, Liu W et al (2015) Resveratrol prevents cadmium activation of Erk1/2 and JNK pathways from neuronal cell death via protein phosphatases 2A and 5. J Neurochem 135:466–478PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Schweiger S, Matthes F, Posey K, Kickstein E, Weber S, Hettich MM et al (2017) Resveratrol induces dephosphorylation of Tau by interfering with the MID1-PP2A complex. Sci Rep 7:13753PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Zamin LL, Dillenburg-Pilla P, Argenta-Comiran R, Horn AP, Simão F, Nassif M, Gerhardt D, Frozza RL, Salbego C (2006) Protective effect of resveratrol against oxygen-glucose deprivation in organotypic hippocampal slice cultures: Involvement of PI3-K pathway. Neurobiol Dis 24:170–182PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Abdel-Aleem GA, Khaleel EF (2017) Rutin hydrate ameliorates cadmium chloride-induced spatial memory loss and neural apoptosis in rats by enhancing levels of acetylcholine, inhibiting JNK and ERK1/2 activation and activating mTOR signalling, Arch Physiol Biochem 124:367–377PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Xiaobin L, Zhonghua QI, Zhao L, YU Z (2016) Astaxanthin reduces type 2 diabeticassociated cognitive decline in rats via activation of PI3K/Akt and attenuation of oxidative stress. Mol Med Rep 13:973–979CrossRefGoogle Scholar
  50. 50.
    Bevins RA, Besheer J (2006) Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study ‘recognition memory’. Nat Protoc 1:1306–1311PubMedCrossRefGoogle Scholar
  51. 51.
    Zhang Y, Xu Z, Wang H, Dong Y, Shi HN, Culley DJ (2012) Anesthetics isoflurane and desflurane differently affect mitochondrial function, learning, and memory. Ann Neurol 71(5):687–698PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Gil HW, Kang EJ, Lee KH, Yang JO, Lee EY, Hong SY (2011) Effect of glutathione on the cadmium chelation of EDTA in a patient with cadmium intoxication. Hum Exp Toxicol 30:79–83PubMedCrossRefGoogle Scholar
  53. 53.
    Mahdavi S, Khodarahmi P, Roodbari NH (2018) Effects of cadmium on Bcl-2/Bax expression ratio in rat cortex brain and hippocampus. Hum Exp Toxicol 37:321–328PubMedCrossRefGoogle Scholar
  54. 54.
    Yuan L, Wang J, Xiao H, Xiao C, Wang Y, Liu X (2012) Isoorientin induces apoptosis through mitochondrial dysfunction and inhibition of PI3K/Akt signaling pathway in HepG2 cancer cells. Toxicol Appl Pharmacol 265:83–92PubMedCrossRefGoogle Scholar
  55. 55.
    Tsuruta F, Masuyama N, Gotoh Y (2002) The phosphatidylinositol 3-kinase (PI3K)-Akt pathway suppresses Bax translocation to mitochondria. J Biol Chem 277:14040–14047PubMedCrossRefGoogle Scholar
  56. 56.
    Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC (1998) Regulation of cell death protease caspase-9 by phosphorylation. Science 282:1318–1321PubMedCrossRefGoogle Scholar
  57. 57.
    Lien EC, Lyssiotis CA, Juvekar A, Hu H, Asara JM, Cantley LC et al (2016) Glutathione biosynthesis is a metabolic vulnerability in PI3K/Akt-driven breast cancer. Nat Cell Biol 18:572–578PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Das S (2005) Resveratrol-mediated activation of cAMP response element-binding protein through adenosine A3 receptor by Akt-dependent and -independent pathways. J Pharmacol Exp Ther 314:762–769PubMedCrossRefGoogle Scholar
  59. 59.
    Crews L, Masliah E (2010) Molecular mechanisms of neurodegeneration in Alzheimer’s disease. Hum Mol Genet 15:12–20CrossRefGoogle Scholar
  60. 60.
    Thatcher RW, Lester ML, McAlaster R, Horst R (1982) Effects of low levels of cadmium and lead on cognitive functioning in children. Arch Environ Health 37:159–166PubMedCrossRefGoogle Scholar
  61. 61.
    Marlowe M, Errera J, Jacobs J (1983) Increased lead and cadmium burdens among mentally retarded children and children with borderline intelligence. Am J Ment Defic 87:477–483PubMedGoogle Scholar
  62. 62.
    Nagymajtenyi DL, Schulz H (1998) Behavioural and neurotoxicological changes caused by cadmium treatment of rats during development. J Appl Toxicol 18:63–70PubMedCrossRefGoogle Scholar
  63. 63.
    Akinyem AJ, Oboh J, Fadaka AO (2017) Curcumin administration suppress acetylcholinesterase gene expression in cadmium treated rats. Neurotoxicology 62:75–79CrossRefGoogle Scholar
  64. 64.
    Carageorgiou H, Tzotzes V, Sideris A, Zarros A, Tsakiris S (2005) Cadmium effects on brain acetylcholinesterase activity and antioxidant status of adult rats: modulation by zinc, calcium and L-cysteine co-administration. Basic Clin Pharmacol Toxicol 97:320–324PubMedCrossRefGoogle Scholar
  65. 65.
    Blokland A (1996) Acetylcholine: a neurotransmitter for learning and memory. Brain Res Rev 21:285–300CrossRefGoogle Scholar
  66. 66.
    Pari L, Murugavel P (2007) Diallyl tetrasulfide improves cadmium induced alterations of acetylcholinesterase, ATPases and oxidative stress in brain of rats. Toxicology 234:44–50PubMedCrossRefGoogle Scholar
  67. 67.
    Heo HJ, Kim MJ, Lee JM, Choi SJ, Cho HY, Hong B, Kim HK, Kim E, Shin DH (2004) Naringenin from Citrus junos has an inhibitory effect on acetylcholinesterase and as mitigating effect on amnesia. Dement Geriatr Cogn Disord 17:151–157PubMedCrossRefGoogle Scholar
  68. 68.
    Tota S, Awasthi H, Kamat PK, Nath C, Hanif K (2010) Protective effect of quercetin against intracerebral streptozotocin induced reduction in cerebral blood flow and impairment of memory in mice. Behav Brain Res 209:73–79PubMedCrossRefGoogle Scholar
  69. 69.
    Liu SJ, Zhang JY, Li HL, Nath C, Hanif K (2004) Tau becomes a more favorable substrate for GSK-3 when it is prephosphorylated by PKA in rat brain. J Biol Chem 279:50078–50088PubMedCrossRefGoogle Scholar
  70. 70.
    Ben P, Zhang Z, Zhu Y, Xiong A, Gao Y, Mu J, Yin Z, Luo L (2016) L-Theanine attenuates cadmium-induced neurotoxicity through the inhibition of oxidative damage and Tau hyperphosphorylation. Neurotoxicology 57:95–103PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Shi HR, Zhu LQ, Wang SH, Liu XA, Tian Q, Zhang Q, Wang Q, Wang JZ (2008) 17β-estradiol attenuates glycogen synthase kinase-3β activation and Tau hyperphosphorylation in Akt-independent manner. J Neural Transm 115:79–888CrossRefGoogle Scholar
  72. 72.
    He J, Yamada K, Zou LB, Nabeshima T (2001) Spatial memory deficit and neurodegeneration induced by the direct injection of okadaic acid into the hippocampus in rats. J Neural Transm 108:1435–1443PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Wang SH, Shih YL, Kuo TC, Shih CM (2009) Cadmium toxicity toward autophagy through ROS-activated GSK-3b in mesangial cells. Toxicol Sci 108:124–131PubMedCrossRefGoogle Scholar
  74. 74.
    Wang JZ, Grundke-Iqbal I, Iqbal K (2007) Kinases and phosphatases and Tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci 25:59PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Moule SK, Welsh GI, Edgell NJ, Foulstone EJ, Proud CG, Denton RM (1997) Regulation of protein kinase B and glycogen synthase kinase-3 by insulin and beta-adrenergic agonists in rat epididymal fat cells. Activation of protein kinase B by wortmannin-sensitive and -insensitive mechanisms. J Biol Chem 272:7713–7719PubMedCrossRefGoogle Scholar
  76. 76.
    Persad S, Attwell S, Gray V, Mawji N, Deng JT, Leung D et al (2001) Regulation of protein kinase B/Akt-serine 473 by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343. J Biol Chem 276:27462–27469PubMedCrossRefGoogle Scholar
  77. 77.
    Chen S, Xiao X, Feng X, Li W, Zhou N, Zheng L, Sun Y, Zhang Z, Zhu W (2012) Resveratrol induces Sirt1-dependent apoptosis in 3T3-L1 preadipocytes by activating AMPK and suppressing AKT activity and survivin expression. J Nutr Biochem 23(9):1100–1112PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Yang YJ, Hu L, Xia YP, Jiang CY, Miao C, Yang CQ, Yuan M, Wang L (2016) Resveratrol suppresses glial activation and alleviates trigeminal neuralgia via activation of AMPK. J Neuroinflamm 13(1):84CrossRefGoogle Scholar
  79. 79.
    Tao R, Gong J, Luo X, Zang M, Guo W, Wen R, Luo Z (2010) AMPK exerts dual regulatory effects on the PI3K pathway. J Mol Signal 18:5:1Google Scholar
  80. 80.
    Domise M, Vingtdeux V (2016) AMPK in neurodegenerative diseases. EXS 107:153–177PubMedGoogle Scholar
  81. 81.
    Martin G, Frasch (2014) Putative role of AMPK in fetal adaptive brain shut-down: linking metabolism and inflammation in the brain. Front Neurol 5:150Google Scholar
  82. 82.
    Wang L, Liu BJ, Cao Y, Xu WQ, Sun DS, Li MZ, Shi FX, Li M, Tian Q, Wang JZ, Zhou XW (2018) Deletion of type-2 cannabinoid receptor induces Alzheimer’s disease-like Tau pathology and memory impairment through AMPK/GSK3β pathway. Mol Neurobiol 55:4731–4744PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Biology, College of ScienceKing Khalid UniversityAbhaSaudi Arabia

Personalised recommendations